Skip to main content
. 2018 May 25;10(6):160. doi: 10.3390/cancers10060160

Figure 1.

Figure 1

Survival of patients with advanced pancreatic cancer receiving pelareorep in combination with gemcitabine. (A) Spider plot showing the change in tumor size at each 6 week time point for 29 patients; (B) progression free survival and overall survival for all patients on study.